-
Je něco špatně v tomto záznamu ?
Tumor regression grading after neoadjuvant treatment of esophageal and gastroesophageal junction adenocarcinoma: results of an international Delphi consensus survey
G. Saliba, S. Detlefsen, F. Carneiro, J. Conner, R. Dorer, JF. Fléjou, H. Hahn, K. Kamaradova, L. Mastracci, SL. Meijer, E. Sabo, K. Sheahan, R. Riddell, N. Wang, RK. Yantiss, L. Lundell, D. Low, M. Vieth, F. Klevebro
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články
- MeSH
- adenokarcinom patologie terapie MeSH
- delfská metoda MeSH
- gastroezofageální junkce patologie MeSH
- konsensus MeSH
- lidé MeSH
- nádory jícnu patologie terapie MeSH
- neoadjuvantní terapie metody MeSH
- odběr biologického vzorku metody normy MeSH
- stupeň nádoru metody MeSH
- výsledek terapie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
Complete histopathologic tumor regression after neoadjuvant treatment is a well-known prognostic factor for survival among patients with adenocarcinomas of the esophagus and gastroesophageal junction. The aim of this international Delphi survey was to reach a consensus regarding the most useful tumor regression grading (TRG) system that could represent an international standard for histopathologic TRG grading of gastroesophageal carcinomas. Fifteen pathologists with special interest in esophageal and gastric pathology participated in the online survey. The initial questionnaire contained of 43 statements that addressed the following topics: (1) specimen processing, (2) gross examination, (3) cross sectioning, (4) staining, (5) Barrett's esophagus, (6) TRG systems, and (7) TRG in lymph node (LN). Participants rated the items using a 5-point Likert style scale and were encouraged to write comments for each statement. The expert panel recommended a 4-tiered TRG system for assessing the primary tumor: grade 1: No residual tumor (complete histopathologic tumor regression), grade 2: less than 10% residual tumor (near-complete regression), grade 3: 10%-50% residual tumor (partial regression), grade 4: greater than 50% residual tumor (minimal/no regression), combined with a 3-tiered system for grading therapeutic response in metastatic LNs: grade a: no residual tumor (complete histopathologic TRG), grade b: partial regression (tumor cells and regression), grade c: no regression (no sign of tumor response). This TRG grading system can be recommended as an international standard for histopathologic TRG grading in esophageal and gastroesophageal junction adenocarcinoma.
Centro Hospitalar Universitário de São João 4200 319 Porto Portugal
Department of Clinical Pathology Karolinska University Hospital Huddinge 141 86 Stockolm Sweden
Department of Pathology and Laboratory Medicine Weill Cornell Medicine 10065 New York NY USA
Department of Pathology Carmel Medical Center 3436212 Haifa Israel
Department of Pathology Saint Antoine Hospital Pierre et Marie Curie University 75571 Paris France
Department of Pathology Virginia Mason Medical Center 98101 Seattle WA USA
Department of Surgery Odense University Hospital 5000 Odense Denmark
Department of Thoracic Surgery Virginia Mason Medical Center Seattle WA USA
Institute of Pathology Klinikum Bayreuth 95445 Bayreuth Germany
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21026122
- 003
- CZ-PrNML
- 005
- 20211026133205.0
- 007
- ta
- 008
- 211013s2021 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.humpath.2020.11.001 $2 doi
- 035 __
- $a (PubMed)33221343
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Saliba, G $u Department of Upper Abdominal Surgery, Division of Surgery, Department of Clinical Science, Intervention and Technology (CLINTEC), Karolinska University Hospital, Karolinska Institutet, 141 57, Huddinge, Stockholm, Sweden. Electronic address: gabriel.saliba@sll.se
- 245 10
- $a Tumor regression grading after neoadjuvant treatment of esophageal and gastroesophageal junction adenocarcinoma: results of an international Delphi consensus survey / $c G. Saliba, S. Detlefsen, F. Carneiro, J. Conner, R. Dorer, JF. Fléjou, H. Hahn, K. Kamaradova, L. Mastracci, SL. Meijer, E. Sabo, K. Sheahan, R. Riddell, N. Wang, RK. Yantiss, L. Lundell, D. Low, M. Vieth, F. Klevebro
- 520 9_
- $a Complete histopathologic tumor regression after neoadjuvant treatment is a well-known prognostic factor for survival among patients with adenocarcinomas of the esophagus and gastroesophageal junction. The aim of this international Delphi survey was to reach a consensus regarding the most useful tumor regression grading (TRG) system that could represent an international standard for histopathologic TRG grading of gastroesophageal carcinomas. Fifteen pathologists with special interest in esophageal and gastric pathology participated in the online survey. The initial questionnaire contained of 43 statements that addressed the following topics: (1) specimen processing, (2) gross examination, (3) cross sectioning, (4) staining, (5) Barrett's esophagus, (6) TRG systems, and (7) TRG in lymph node (LN). Participants rated the items using a 5-point Likert style scale and were encouraged to write comments for each statement. The expert panel recommended a 4-tiered TRG system for assessing the primary tumor: grade 1: No residual tumor (complete histopathologic tumor regression), grade 2: less than 10% residual tumor (near-complete regression), grade 3: 10%-50% residual tumor (partial regression), grade 4: greater than 50% residual tumor (minimal/no regression), combined with a 3-tiered system for grading therapeutic response in metastatic LNs: grade a: no residual tumor (complete histopathologic TRG), grade b: partial regression (tumor cells and regression), grade c: no regression (no sign of tumor response). This TRG grading system can be recommended as an international standard for histopathologic TRG grading in esophageal and gastroesophageal junction adenocarcinoma.
- 650 _2
- $a adenokarcinom $x patologie $x terapie $7 D000230
- 650 _2
- $a konsensus $7 D032921
- 650 _2
- $a delfská metoda $7 D003697
- 650 _2
- $a nádory jícnu $x patologie $x terapie $7 D004938
- 650 _2
- $a gastroezofageální junkce $x patologie $7 D004943
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a neoadjuvantní terapie $x metody $7 D020360
- 650 _2
- $a stupeň nádoru $x metody $7 D060787
- 650 _2
- $a odběr biologického vzorku $x metody $x normy $7 D013048
- 650 _2
- $a výsledek terapie $7 D016896
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Detlefsen, S $u Department of Pathology, Odense University Hospital, Denmark& Dept. of Clinical Research, Faculty of Health Sciences, University of Southern Denmark, 5000, Odense, Denmark
- 700 1_
- $a Carneiro, F $u Centro Hospitalar Universitário de São João (CHUSJ)/Faculty of Medicine of the University of Porto (FMUP) and Instituto de Investigação e Inovação Em Saúde (i3S)/Institute of Molecular Pathology and Immunology of the University of Porto (Ipatimup), 4200-319, Porto, Portugal
- 700 1_
- $a Conner, J $u Department of Laboratory Medicine and Pathobiology, Mount Sinai Hospital, University of Toronto, M5G 1X5, Toronto, Canada
- 700 1_
- $a Dorer, R $u Department of Pathology, Virginia Mason Medical Center, 98101, Seattle, WA, USA
- 700 1_
- $a Fléjou, J F $u Department of Pathology, Saint-Antoine Hospital, Pierre et Marie Curie University, 75571, Paris, France
- 700 1_
- $a Hahn, H $u Department of Pathology, Virginia Mason Medical Center, 98101, Seattle, WA, USA
- 700 1_
- $a Kamaradova, K $u The Fingerland Department of Pathology, Charles University Faculty of Medicine and University Hospital Hradec Králové, Hradec Králové, 500 03, Czech Republic
- 700 1_
- $a Mastracci, L $u Division of Anatomic Pathology, Department of Surgical Science and Integrated Diagnostics (DISC), University of Genoa and Ospedale Policlinico IRCCS San Martino, 16126, Genoa, Italy
- 700 1_
- $a Meijer, S L $u Department of Pathology, Amsterdam University Medical Centers, Location AMC, 1081 HV, Amsterdam, the Netherlands
- 700 1_
- $a Sabo, E $u Department of Pathology, Carmel Medical Center, 3436212, Haifa, Israel
- 700 1_
- $a Sheahan, K $u Department of Pathology, St Vincent's University Hospital & UCD School of Medicine, Dublin, D04 T6F4, Ireland
- 700 1_
- $a Riddell, R $u Department of Laboratory Medicine and Pathobiology, Mount Sinai Hospital, University of Toronto, M5G 1X5, Toronto, Canada
- 700 1_
- $a Wang, N $u Department of Clinical Pathology, Karolinska University Hospital, Huddinge, 141 86, Stockolm, Sweden
- 700 1_
- $a Yantiss, R K $u Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, 10065, New York, NY, USA
- 700 1_
- $a Lundell, L $u Department of Upper Abdominal Surgery, Division of Surgery, Department of Clinical Science, Intervention and Technology (CLINTEC), Karolinska University Hospital, Karolinska Institutet, 141 57, Huddinge, Stockholm, Sweden; Department of Surgery, Odense University Hospital, 5000, Odense, Denmark
- 700 1_
- $a Low, D $u Department of Thoracic Surgery, Virginia Mason Medical Center, Seattle, WA, USA
- 700 1_
- $a Vieth, M $u Institute of Pathology, Klinikum Bayreuth, 95445, Bayreuth, Germany
- 700 1_
- $a Klevebro, F $u Department of Upper Abdominal Surgery, Division of Surgery, Department of Clinical Science, Intervention and Technology (CLINTEC), Karolinska University Hospital, Karolinska Institutet, 141 57, Huddinge, Stockholm, Sweden
- 773 0_
- $w MED00002080 $t Human pathology $x 1532-8392 $g Roč. 108, č. - (2021), s. 60-67
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/33221343 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20211013 $b ABA008
- 991 __
- $a 20211026133211 $b ABA008
- 999 __
- $a ok $b bmc $g 1714978 $s 1146629
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 108 $c - $d 60-67 $e 20201119 $i 1532-8392 $m Human pathology $n Hum Pathol $x MED00002080
- LZP __
- $a Pubmed-20211013
